Starting Dose of Long-Acting Insulin in Geriatric Patients
For elderly patients (≥65 years) with type 2 diabetes who are insulin-naïve, initiate long-acting basal insulin at 0.2 units/kg or up to 10 units once daily, using the same dosing approach as younger adults. 1
Initial Dosing Strategy
Type 2 Diabetes (Insulin-Naïve)
- Start with 0.2 units/kg body weight OR up to 10 units once daily, whichever is lower 1
- This conservative approach applies equally to geriatric patients, as pharmacokinetic studies show no clinically significant age-related differences in insulin glargine or degludec metabolism 2
- Alternative evidence supports a range of 0.1-0.2 units/kg/day as appropriate starting doses 3, 4, 5
Type 1 Diabetes
- If the geriatric patient has type 1 diabetes, start basal insulin at approximately one-third of total daily insulin requirements, with short-acting insulin covering the remainder 1
Geriatric-Specific Considerations
Pharmacokinetics in Older Adults
- Pharmacokinetic and pharmacodynamic properties of insulin degludec are similar between younger adults (18-35 years) and geriatric patients (≥65 years), though greater between-subject variability exists in older adults 2
- This similarity supports using standard starting doses rather than automatic dose reductions based solely on age 2
Glycemic Targets for Older Adults
- Target fasting glucose of 90-150 mg/dL (5.0-8.3 mmol/L) for most geriatric patients 6
- This target may be adjusted based on overall health status, comorbidities, and goals of care 6
- More relaxed targets are appropriate for frail elderly or those with limited life expectancy 6
Titration Protocol
Weekly Adjustment Schedule
- Titrate based on fasting finger-stick glucose results over 1 week 6
- If ≥50% of fasting values exceed goal: increase dose by 2 units 6
- If >2 fasting values per week are <80 mg/dL (<4.4 mmol/L): decrease dose by 2 units 6
Alternative Titration Approach
- For NPH, insulin detemir, and glargine 100 units/mL: increase by 1 unit per day 3
- For glargine 100/300 units/mL and degludec: increase by 2-4 units once or twice per week 3
Choice of Basal Insulin
Preferred Agents for Geriatric Patients
- Glargine U-300 or degludec U-100 appear most effective when injected at bedtime, followed by glargine U-100 or detemir, then NPH 4
- Degludec and newer glargine formulations (U-300) carry lower risk of hypoglycemia compared to NPH, which is particularly important in older adults 4, 7
- Degludec demonstrates significantly decreased rates of overall and nocturnal hypoglycemia compared to other long-acting insulins 7
Critical Safety Considerations
Hypoglycemia Prevention
- Avoid overbasalization—do not continue escalating doses beyond approximately 0.5-1.0 units/kg/day without meaningful FPG reduction 3
- Consider comorbidities including chronic kidney disease, atherosclerotic cardiovascular disease, and low body weight when selecting additional agents 6
- Increase frequency of glucose monitoring during any insulin regimen changes 1
Administration Timing
- Administer at the same time every day to maintain steady-state levels 1
- For glargine U-100, morning injection may be more effective and cause fewer hypoglycemic events than bedtime injection 4
Renal and Hepatic Impairment
- Mild to severe renal impairment increases insulin degludec exposure by 10-27%, though no systematic dose adjustment is required 2
- Close monitoring is essential in geriatric patients with renal or hepatic dysfunction 1
Common Pitfalls to Avoid
- Do not automatically reduce starting doses in elderly patients based on age alone—use weight-based dosing as in younger adults 1, 2
- Do not use rapid- or short-acting insulin at bedtime during regimen simplification 6
- Rotate injection sites within the same region to prevent lipodystrophy, which can cause erratic absorption 1
- Never share insulin pens or needles between patients, even with needle changes 1